26 reports

  • IMMUNOLOGY THERAPEUTICS MARKET, GLOBAL, ANNUAL REVENUES FOR CIMZIA ($BN), 2006-2022
  • IMMUNOLOGY, GLOBAL, ANNUAL REVENUE FORECAST FOR UPADACITINIB ($M), 2015-2022

Gastrointestinal Cancer Research; ##(##): ##-## Mayo Clinic (2014).

  • Immunology
  • World
  • AbbVie Inc.
  • Janssen Biotech, Inc.
  • Johnson & Johnson
  • Establish ed
  • 4.2 Key Therapy Areas by Indication
  • Immunology
  • Pharmaceutical
  • Therapy
  • Europe
  • Market Size
  • Pipeline Landscape Assessment

Excluded from this report are Crohn' s disease and ulcerative colitis, as they fall under the gastrointestinal disorders therapy area.

  • Immunology
  • World
  • Market Size
  • Johnson & Johnson
  • Novartis AG
  • Research Contact: info@globaldata.com

The gastrointestinal therapeutics market recorded ## partnership deals and six licensing deals worth USD##. ## billion in Q## 2016.

  • Endocrine Disease
  • Immunology
  • World
  • Deals & Alliance
  • AstraZeneca PLC

Gastrointestinal Disorders, Unspecified Nutritional Disorders Completed Phase IV Interventional Nutramigen with Enflora LGG University of Naples Federico II Mead Johnson Nutrition Company ## Oct 2008 ## Jun 2010 ## ## A Real Life Study of Oral Immunotherapy in Subjects with Severe Food Allerg

  • Biological Therapy
  • Immunology
  • Milk
  • World
  • Product Initiative

Gastrointestinal Disorders, Unspecified Nutritional Disorders Completed Phase IV Interventional Nutramigen with Enflora LGG University of Naples Federico II Mead Johnson Nutrition Company ## Oct 2008 ## Jun 2010 ## ## Clinical Trial profile. ## Trial Title Trial Identifier Secondary ID(s) Ther

  • Clinical Trial
  • Drug Discovery And Development
  • Immunology
  • World
  • Product Initiative
  • UCB SA, Deals By Therapy Area, 2011 to YTD 2017

The company' s generic products are used for the treatment of conditions such as gastrointestinal disorders, oncology, cardiovascular diseases, pain management, Central Nervous System, cancer, pain, infectious diseases and pediatrics.

  • Autoimmune Disease
  • Immunology
  • United States
  • Company
  • UCB S.A.
  • Pipeline Products by Therapy Area and Proportion of Established and First-in-
  • First-in-class Pipeline Products by Therapy Area and Stage of Development, Q1

CBR PHARMA INSIGHTS Innovation Tracking Factbook 2016 - An Assessment of the Pharmaceutical Pipeline Published: June 2016 Report Code: GBI##CBR www. gbiresearch. com ## Introduction Innovation is a crucial element of the pharmaceutical industry.

  • Immunology
  • Pharmaceutical
  • Europe
  • Company
  • Merck & Co., Inc.
  • Clinical Trial profile. 532 Trial Title
  • Clinical Trial profile. 883 Trial Title

Host Disease Randomized Study of Oral Beclomethasone Dipropionate with Ten Days of Prednisone for Treatment of Gastrointestinal GVHD GDCT## NCT##, ENT ##-## Immunology Graft Versus Host Disease (GVHD), Unspecified Gastrointestinal Disorders Completed Phase III Interventi

  • Drug Discovery And Development
  • Immunology
  • Pharmaceutical
  • United States
  • World

Gastrointestinal Disorders, Unspecified Infectious Diseases Terminated Phase III Interventional bifidobacterium animalis lactis University of Copenhagen Chr.

  • Clinical Trial
  • Immunology
  • Pharmaceutical
  • Japan
  • World
  • Clinical Trial profile. 103 Trial Title
  • Clinical Trial profile. 865 Trial Title

Host Disease Randomized Study of Oral Beclomethasone Dipropionate with Ten Days of Prednisone for Treatment of Gastrointestinal GVHD GDCT## NCT##, ENT ##-## Immunology Graft Versus Host Disease (GVHD), Unspecified Gastrointestinal Disorders Completed Phase III Interventi

  • Clinical Trial
  • Immunology
  • Pharmaceutical
  • World
  • Product Initiative

Overall, there was one serious adverse event of moderate gastrointestinal infection that was determined by the investigator not to be drug-related.

  • Clinical Trial
  • Immunology
  • World
  • Product Initiative
  • Shire plc

Gastrointestinal Tolerability and Efficacy of Enteric-coated Mycophenolate Sodium (Myfortic) in Heart Transplant Recipients Enteric-coated Mycophenolate Sodium (Myfortic) in Heart Transplant Recipients GDCT## NCT##, ## Immunology Heart Transplant Rejection, Unspecified

  • Heart Transplant
  • Immunology
  • World
  • Product Initiative
  • Novartis AG
  • Clinical Trial profile. 671 Trial Title
  • Clinical Trial profile. 129 Trial Title

Gastrointestinal Symptoms A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-Coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) was Reduced Due to Gastrointestinal Symptoms GDCT## NCT##, CERL##

  • Clinical Trial
  • Immunology
  • Prosthesis
  • Transplantation
  • Novartis AG

Gastrointestinal Tolerability of Mycophenolate Mofetil (MMF, Cellcept) and Enteric-coated Mycophenolate Sodium (EC-MPS, Myfortic) in Maintenance Transplant Patients Treated with Calcineurin Inhibitors Gastrointestinal Tolerability of MMF vs EC-MPS in Maintenance Transplant Patients

  • Immunology
  • Lung Transplant
  • World
  • Product Initiative
  • Novartis AG

Gastrointestinal Tolerability of Mycophenolate Mofetil (MMF, Cellcept) and Enteric-coated Mycophenolate Sodium (EC-MPS, Myfortic) in Maintenance Transplant Patients Treated with Calcineurin Inhibitors Gastrointestinal Tolerability of MMF vs EC-MPS in Maintenance Transplant Patients

  • Blood Supply, Tissue Banking And Transplantation
  • Drug Discovery And Development
  • Immunology
  • World
  • Product Initiative

Gastrointestinal Bleeding (Gastrointestinal Hemorrhage), Hemophilia, Hemorrhage, Hereditary Angioedema (HAE) (C## Esterase Inhibitor [C##-INH] Deficiency), Menorrhagia, Metrorrhagia (Abnormal Uterine Bleeding), Transfusion Hemosiderosis Completed Phase I Interventional Cyklonova Alte

  • Allergy Drug
  • Immunology
  • World
  • Product Initiative
  • Shire plc
  • Versatile Innovation in Immunology, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area and Breakdown of
  • cerdulatinib

Crohn' s disease and ulcerative colitis are excluded from this report, as these are primarily categorized as gastrointestinal disorders.

  • Health Services
  • Healthcare
  • Immunology
  • World
  • GlaxoSmithKline plc

This collagen accumulation causes scarring (fibrosis) of the skin, and in the case of systemic scleroderma, also affects internal organs such as the lungs, the kidneys and gastrointestinal system.

  • Clinical Trial
  • Drug Discovery And Development
  • Immunology
  • World
  • Product Initiative

gastrointestinal, neuroscience, oncology, respiratory, inflammation and infection.

  • Immunology
  • United States
  • Company
  • M&A
  • MedImmune, LLC
  • CLINICAL TRIAL PROFILE. 165 TRIAL TITLE

In addition, transdermal delivery avoids the gastrointestinal tract and potential stomach acid degradation of CBD into THC (associated with psychoactive effects), as demonstrated in a Zynerba in vitro study.

  • Arthritis
  • Clinical Trial
  • Immunology
  • World
  • Pfizer Inc.

Gastrointestinal Graft- Versus-Host Disease and the Potential Interaction with Fluconazole or Voriconazole Evaluation of Budesonide and How It Interacts with Antifungal Drugs in People with Gastrointestinal Graft-versus-host Disease GDCT## NCT##, ##; ##-H-## Immunol

  • Blood Supply, Tissue Banking And Transplantation
  • Clinical Trial
  • Immunology
  • World
  • Product Initiative
  • Institute for Research in Immunology and Cancer, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017

gastrointestinal therapy area with two deals during the period 2011 to YTD 2017.

  • Health Services
  • Immunology
  • Pharmaceutical
  • Canada
  • GlobalData's company
  • La Jolla Institute for Allergy & Immunology, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017

GlobalData Therapy Area Gastrointestinal Infectious Disease Metabolic Disorders Oncology Respiratory No. of Deals ## ## ## ## ## Deal Value (US$ million) NA NA NA NA NA La Jolla Institute for Allergy & Immunology, Medical Devices Deals, 2011 to YTD 2017 La Jolla Institute for Allergy & I

  • Immunology
  • Pharmaceutical
  • United States
  • Deals & Alliance
  • GlobalData's company

Note: Deals include all announced pharmaceuticals & healthcare deals from 2011 onwards, GlobalData University of Montreal, Deals By Therapy Area, 2011 to YTD 2017 Therapy Area Cardiovascular Central Nervous System Gastrointestinal Immunology Infectious Disease Metabolic Disorders Oncolo

  • Healthcare
  • Immunology
  • Pharmaceutical
  • Canada
  • GlobalData's company

The company' s research resources are focused on asthma, chronic obstructive pulmonary disease (COPD), gastrointestinal disorders, psoriasis and other dermatological conditions.

  • Healthcare
  • Hospital
  • Immunology
  • Pharmaceutical
  • BioFocus DPI Limited